Clinical Trial Update: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated switching from Efavirenz to Lopinavir/Ritonavir in HIV-infected patients with lipoatrophy; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Lipoatrophy

Drugs mentioned

• Kaletra (lopinavir)
• Sustiva (efavirenz)

Snippet

Sponsor: Juan A. Arnaiz | Conditions: HIV Infections, Lipoatrophy | Phase 4 | Status: COMPLETED